The article reports that scientists at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, have partnered with the U.S. Oncology Research of The Woodlands, Texas, and Life Technologies to use whole-genome sequencing (WGS) to devise better treatment strategies. Similarly a 2011 pilot study at the University of Michigan coupled genome and transcriptome sequencing on tumors and showed how mutations could in potential beneficial drug trials for patients.